Profile data is unavailable for this security.
About the company
Zai Lab Ltd is a holding company mainly engaged in the biopharmaceutical field. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including oncology, autoimmune and infectious diseases fields. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include Niraparib (ZL-2306), ZL-2103, ZL-1101 and others.
- Revenue in HKD (TTM)2.51bn
- Net income in HKD-2.32bn
- Incorporated2013
- Employees2.18k
- LocationZai Lab Ltd4560 Jinke Road, Bldg. 1, 4/F, PudongSHANGHAI 201210ChinaCHN
- Phone+86 2 161632588
- Fax+86 2 161632570
- Websitehttps://www.zailaboratory.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3SBio Inc | 9.08bn | 1.79bn | 13.99bn | 5.61k | 7.96 | 0.9023 | 6.31 | 1.54 | 0.7339 | 0.7339 | 3.73 | 6.47 | 0.3575 | 1.52 | 6.87 | 1,677,561.00 | 7.25 | 7.44 | 10.26 | 9.29 | 85.94 | 82.91 | 20.27 | 21.50 | 1.57 | 141.55 | 0.1998 | -- | 13.84 | 11.26 | -19.13 | 3.94 | 8.78 | -- |
| Simcere Pharmaceutical Group Ltd | 6.84bn | -1.19bn | 16.47bn | 6.41k | -- | 2.23 | -- | 2.41 | -0.4543 | -0.4543 | 2.65 | 2.93 | 0.5198 | 2.19 | 2.64 | 972,792.20 | -9.04 | 10.17 | -11.71 | 15.60 | 77.02 | 78.82 | -17.40 | 17.50 | 1.88 | 0.4721 | 0.1461 | 46.68 | 4.49 | 7.92 | -23.22 | -0.5213 | 23.93 | -- |
| Grand Pharmaceutical Group Ltd | 10.59bn | 2.41bn | 17.32bn | 10.78k | 7.09 | 1.10 | 6.02 | 1.64 | 0.6885 | 0.6885 | 3.03 | 4.43 | 0.4472 | 3.62 | 4.54 | 1,005,064.00 | 10.25 | 10.09 | 14.21 | 14.01 | 59.00 | 61.97 | 22.92 | 22.35 | 1.09 | -- | 0.2232 | 26.94 | 10.12 | 12.06 | -9.59 | 21.41 | 5.69 | 24.77 |
| The United Laboratories Intl. Hldgs Ltd. | 15.10bn | 3.13bn | 18.42bn | 15.00k | 5.88 | 1.26 | 4.92 | 1.22 | 1.73 | 1.73 | 8.31 | 8.02 | 0.6578 | 3.30 | 5.67 | 1,006,664.00 | 13.65 | 7.89 | 20.72 | 12.64 | 46.15 | 44.17 | 20.75 | 12.73 | 1.72 | -- | 0.1532 | 28.99 | 21.22 | 12.84 | 70.85 | 31.66 | 24.19 | 46.04 |
| China Medical System Holdings Ltd | 7.56bn | 1.50bn | 18.76bn | 5.78k | 12.54 | 1.08 | 10.80 | 2.48 | 0.6134 | 0.6134 | 3.09 | 7.10 | 0.384 | 2.89 | 5.65 | 1,326,150.00 | 7.51 | 18.44 | 8.53 | 21.14 | 74.13 | 75.47 | 19.56 | 34.26 | 3.97 | -- | 0.0667 | 40.14 | -12.43 | 8.08 | -26.33 | 5.35 | 38.69 | 5.19 |
| HUTCHMED (China) Ltd | 4.75bn | -326.34m | 24.14bn | 1.97k | -- | 4.19 | -- | 5.08 | -0.3883 | -0.3883 | 5.51 | 6.60 | 0.4775 | 7.10 | 4.15 | 2,389,026.00 | -3.30 | -14.35 | -4.65 | -20.43 | 41.67 | 36.57 | -6.91 | -31.44 | 2.68 | -- | 0.0984 | -- | 96.52 | 31.38 | 127.93 | -- | 38.65 | -- |
| Zai Lab Ltd | 2.51bn | -2.32bn | 24.35bn | 2.18k | -- | 4.38 | -- | 9.71 | -2.39 | -2.39 | 2.58 | 5.58 | 0.3083 | 3.04 | 5.52 | -- | -28.50 | -37.72 | -34.92 | -42.72 | 63.17 | 64.75 | -92.44 | -282.44 | 3.29 | -- | 0.0908 | -- | 24.03 | 360.03 | 24.51 | -- | -3.45 | -- |
| WuXi XDC Cayman Inc | 3.01bn | 640.85m | 31.97bn | 1.50k | 50.62 | 4.94 | 43.80 | 10.61 | 0.5265 | 0.5265 | 2.66 | 5.39 | 0.5586 | 21.31 | 2.85 | 2,557,931.00 | 11.88 | -- | 15.43 | -- | 30.96 | -- | 21.27 | -- | 4.02 | -- | 0.0113 | -- | 114.44 | -- | 82.07 | -- | -- | -- |
| China Resources Pharmaceutical Group Ltd | 270.06bn | 4.07bn | 35.06bn | 72.76k | 8.62 | 0.6725 | 2.81 | 0.1298 | 0.6477 | 0.6477 | 42.99 | 8.30 | 0.966 | 6.09 | 3.28 | 3,700,141.00 | 3.19 | 3.02 | 12.13 | 11.35 | 15.78 | 15.72 | 3.31 | 2.87 | 1.12 | 11.50 | 0.4396 | 24.73 | 12.16 | 8.86 | 10.11 | 2.80 | 13.58 | 7.05 |
Data as of Nov 13 2024. Currency figures normalised to Zai Lab Ltd's reporting currency: Hong Kong Dollar HKD
22.07%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Wellington Management Co. LLPas of 04 Nov 2024 | 76.12m | 7.64% |
| The Vanguard Group, Inc.as of 02 Oct 2024 | 35.50m | 3.56% |
| Credit Suisse Asset Management (Schweiz) AGas of 30 Aug 2024 | 27.09m | 2.72% |
| Baillie Gifford & Co.as of 30 Sep 2024 | 16.24m | 1.63% |
| GF Fund Management Co., Ltd.as of 30 Jun 2024 | 12.26m | 1.23% |
| Wellington Management International Ltd.as of 04 Nov 2024 | 12.19m | 1.22% |
| BlackRock Fund Advisorsas of 03 Oct 2024 | 10.76m | 1.08% |
| UBS Asset Management Switzerland AGas of 09 May 2024 | 10.20m | 1.02% |
| FIAM LLCas of 04 Nov 2024 | 10.09m | 1.01% |
| Wellington Management Hong Kong Ltd.as of 04 Nov 2024 | 9.36m | 0.94% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
